Humanigen Inc (OTCMKTS: HGEN) is likely to see tremendous gains in the market when the opening bell rings. That’s because the company issued a press release this morning, announcing that it has made progress toward sending its COVID-19 treatment candidate into Phase III studies. Here’s what’s going on:
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
HGEN Stock To Run On COVID-19 Phase III Announcement
In a press release issued early this morning, Humanigen said that it has submitted all initial protocal synopsis to the FDA in support of its plans to initiate a Phase III clinical study. This is a key step in pushing for the multi-center, United States-based, study.
If approved, HGEN said that the study will be a randomized, controlled, clinical trial. The trial will surround the use of lenzilumab as a both a preventative measure and a treatment for cytokine storm.
Cytokine storm takes place when the body has an excessive immune response to a virus, generally in the lungs. When this takes place, excessive immune cells and the cytokines that activate them rush to the lungs, leading to additional fluids on the lungs.
In COVID-19 patients, cytokine storm is known to lead to ARDS, or acute respiratory distress syndrome, as well as pneumonia. So, the ability to prevent or treat cytokine storm equates to the ability to improve patient chances of recovering from COVID-19.
In a statement, Dr. Cameron Durrant, CEO at HGEN, had the folllowing to offer:
Humanigen has pioneered the field of GM-CSF neutralization and, unlike others, has already conducted two Phase I and two Phase II studies, including in patients with severe respiratory conditions, with excellent safety results. We have been working on prevention of cytokine storm for nearly three years. Lenzilumab has an excellent safety and tolerability profile and has not been associated with serious adverse events, including in patients who are immunosuppressed or with severe asthma. Subject to discussion and agreement with regulatory authorities, we intend to progress as quickly as possible with this study.
The Strategic Advantages Here Are Hard To Ignore
While there are plenty of companies working to stop the spread of the coronavirus, in the world of treatments for the condition, Humanigen is far ahead of its compeition. You see, only a handful of companies have announced that they are working on treatments, rather than vaccines, for COVID-19. An even smaller number of companies has anything tangible, and when it comes to having a Phase III-ready asset ready for study, well, even fewer fit this criteria.
HGEN is one of those very few companies that has a Phase III-ready candidate. This alone is a strategic advantage. After all, in the face of a pandemic, speed to market is everything. With a candidate that’s ready to head into Phase III trials, speed is on the company’s side. However, that’s not the only strategic advantage here.
The truth of the matter is that the company has been studying, and working to fight against cytokine storms for some time now. Let’s face it, a Phase III candidate isn’t going to pop up over night.
In the past, HGEN has worked to prevent cytokine storms in cancer patients treated with CAR-T therapies, in asthma patients, and in patients in other populations. In previous clinical trials, the treatment has not only shown to be effective in both the prevention and treatment of cytokine storms, it has proven to uphold a compelling safety and tolerability profile.
Considering the fact that Humanigen has already displayed efficacy and safety in the prevention of cytokine storms, all the company needs to do now is prove that the same results can be seen in a population of high-risk COVID-19 patients.
The Market Opportunity Here Is Tremendous
Should all go well, the market opportunity for HGEN is tremendous. Think about it, when was the last time that you saw a pandemic shut down schools, put an end to events, and change life as you knew it. Chances are that your answer is NEVER.
The bottom line is that as the pandemic spreads, the need for treatment options is becoming more urgent. Of course, the world is pushing for vaccines as well, but vaccines aren’t the end all be all. After all, we have a flu vaccine, but more than 50,000 people die every year from the condition.
The truth is that we need a treatment, and as the pandemic spreads, demand for that treatment will only grow. With HGEN being well ahead of its competition, and having evidence that its lenzilumab candidate is effective in preventing and treating cytokine storm, this is a stock that investors should not ignore.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Get Free Alerts
Join our free mailing list to receive stock alerts!
This website/newsletter is owned, operated and edited by CNA Finance, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “CNA Finance” refers to CNA Finance, LLC. This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to publish information and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners do not own any shares in stocks mentioned unless stated in page disclosures. If we own any shares we will list the information relevant to the stock and number of shares here. CNA Finance, parent company to Alpha Stock News, receives payment to publish content and promote publicly traded companies. Pursuant to an agreement between CNA Finance and Humanigen, CNA Finance has been hired for a period beginning on 3/23/20 and ending on 4/323/20 to conduct digital advertising and marketing and publicly disseminate information about HGEN via Websites and Email. We have an agreement and are currently owed $10,000 by via bank wire transfer to cover the cost of content production. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated digital outreach efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of digital outreach marketing, which may end as soon as the marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct and Humanigen has not approved the content of this site. Furthermore, CNA Finance often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.